CN110833595A - Traditional Chinese medicine composition for treating gout and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN110833595A CN110833595A CN201810957243.2A CN201810957243A CN110833595A CN 110833595 A CN110833595 A CN 110833595A CN 201810957243 A CN201810957243 A CN 201810957243A CN 110833595 A CN110833595 A CN 110833595A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- gout
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating gout and a preparation method thereof, belonging to the field of traditional Chinese medicines; the gout traditional Chinese medicine composition comprises, by weight, 40-80 parts of cyclocarya paliurus, 10-40 parts of corn stigma, 5-30 parts of kudzu root and 5-30 parts of lalang grass rhizome. The composition is prepared by mixing the raw materials according to a certain proportion, decocting, concentrating, drying, pulverizing, sieving, and finally packaging. The anti-gout traditional Chinese medicine composition provided by the invention is simple in formula and simple and convenient in preparation process, and can well retain active ingredients of the composition. The effect of the prescription for treating gout is better than the curative effect of a single traditional Chinese medicine and any two-traditional Chinese medicine combination and three-traditional Chinese medicine combination of the prescription, the synergistic effect of the single traditional Chinese medicine in the prescription can be exerted to improve the clinical symptoms of acute gout attack joint redness and swelling and pain and slow down the attack of complications of patients with chronic gout, and the prescription has the characteristics of convenience in taking, safety and no toxic or side effect.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating gout and a preparation method thereof.
Background
Gout is caused by hyperuricemia (serum uric acid concentration > 420umol/L) causing crystallization of sodium urate, deposition on joints and cartilage tissue around joints, causing accumulation of neutrophils and joint synovial cells to The sodium urate crystallization sites, release of inflammatory cytokines (IL-1 β, TNF- α), and severe inflammatory response caused by chemokines [ Miguel A. Martillo, LamaNazzal, Dariab. Cfitenden The crystallization of monocondium urate. Current Rheumatomatoutoxy Reports, 2014, 16 (2): 400 ].
Hyperuricemia is the biochemical basis for gout development. The uric acid content is increased due to the excessive production of uric acid in the body or the reduction of uric acid excretion. Among them, approximately 90% of hyperuricemia is caused by decreased uric acid excretion due to renal uric acid excretion disorder, and the rest is hyperuricemia caused by increased uric acid production due to metabolic disorder of purine substances in the body or excessive purine-rich food intake. [ Ichida Kimiyoshi, Matsuo Hirotaka, Takada Tappei, et al, classified extra-crude mutation is a common house of hyperuricemia. Nature Communications, 2012, 3: 764].
The sodium urate crystal can further activate NLRP3 inflammasome through generating active oxygen, promote the organism to secrete inflammatory cell factors, and further initiate gout.
The course of gout can be divided into asymptomatic hyperuricemia, an acute gout attack, an intermittent gout attack, and a chronic tophus lesion. In addition to the onset of gout causing inflammatory symptoms such as red swelling and pain, complications such as hypertension, hyperlipidemia, hyperglycemia, and cardiovascular diseases are also caused in the late stage of gout [ yanyanyanyan Zhu, bhavirkj Pandya, hyonkchoi. comorbidities of goule and hypemricemia in the US general publication: NHANES 2007-2008.American Journal of Medicine, 2012, 125 (7): 679-687].
Currently, gout treatment is mainly based on controlling joint inflammation caused by acute gout attack and reducing body uric acid [ Khanna Dinesh, PujaP Khanna, john d Fitzgerald et, al.2012 American college of Rheumatology guidelines for management of gout.part 2: thermal and innovative mapping of the amino acids of: 1447-61]. Colchicine, non-steroidal anti-inflammatory drugs and glucocorticoids are mainly used in controlling joint inflammation. Short-term administration of glucocorticoids may be an option when patients develop tolerance to colchicine and non-steroidal anti-inflammatory drugs and severe adverse reactions. The medicine is used for inhibiting excessive production of uric acid and promoting excretion of uric acid in kidney in reducing uric acid in body. In the aspect of reducing the production of uric acid, allopurinol and febuxostat inhibit the production of uric acid in the body by using a key enzyme xanthine oxidase in the purine metabolic process of the body; in promoting uric acid excretion, it mainly acts on urate transporters to promote uric acid renal excretion, such as benzbromarone and probenecid. However, the above drugs have various degrees of adverse reactions. For example, colchicine can cause gastrointestinal reactions such as nausea, vomiting, abdominal pain and bloating, nonsteroidal anti-inflammatory drugs can cause gastrointestinal bleeding, gastrointestinal perforation, allopurinol can cause cutaneous allergic reactions and impairment of hepatic renal function [ Khanna index, PujaPKhanna, john d Fitzgerald, et, al.2012 American College of rhematotoglypeptides for management of gout.part 2: the mpy and anti-natnammatoxyphenylaxis of acid route and its Research, arthritis care Research, 2012, 64 (10): 1447. therefore, the development of a new medicament for treating gout, which is safe and has small side effect and is suitable for long-term administration by patients, is particularly important.
The traditional Chinese medicine is a natural product and is rich in various components, so that the traditional Chinese medicine has the effects of multiple components, multiple targets and overall synergy in the process of treating diseases. In the process of treating diseases, compared with western medicines, the traditional Chinese medicine has the advantages of small side effect, reduction of complications and low treatment cost, so that the traditional Chinese medicine is paid more and more attention in the development process of new medicines.
Aiming at a plurality of adverse reactions existing in the current western medicines for clinically treating gout, the traditional Chinese medicine is a natural medicine, and has the advantages of multiple components and multiple targets, safety and no toxic or side effect compared with the western medicines in the process of treating diseases because the traditional Chinese medicine is rich in a plurality of natural components.
Disclosure of Invention
The invention aims to solve the technical problems that western medicines have high side effects, gout is easy to relapse after stopping medicine and complications caused by gout exist in the existing gout treatment process.
In order to solve the technical problems, the invention discloses the following technical scheme:
a traditional Chinese medicine composition for treating gout comprises the following raw materials in parts by weight:
40-80 parts of cyclocarya paliurus, 10-40 parts of corn stigma, 5-30 parts of kudzu root and 5-30 parts of lalang grass rhizome.
Preferably, the traditional Chinese medicine composition for treating gout comprises the following raw materials in parts by weight: 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae.
Meanwhile, the invention also preferably discloses a preparation method of the traditional Chinese medicine composition for treating gout, which comprises the following steps: mixing the raw materials at a certain ratio, decocting, concentrating, drying, pulverizing, sieving and packaging. The method comprises the following specific steps:
a) adding 8-10 times of distilled water according to the total mass of the mixed raw materials.
b) Decocting the mixture at 80-100 deg.C for 1-2 hr, and continuously decocting for 2-3 times.
c) Concentrating the obtained decoction under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the obtained thick extract at 60-80 deg.C to obtain dry powder.
e) Packaging the dry powder.
Cyclocarya paliurus (Batal) Iljinsk is a tree plant of Cyclocarya paliurus of Juglandaceae, and researches report that the extract of Cyclocarya paliurus leaves has pharmacological effects of reducing blood sugar, reducing blood fat, resisting oxidation, resisting inflammation and the like. Cyclocarya paliurus aqueous extract can obviously reduce malondialdehyde level in blood serum of diabetic rats and obviously increase the levels of SOD (superoxide dismutase) and GSH-Px (glutathione peroxidase) [ Qingqing wang, Cuihua Jiang, Shengzuo Fang, et, al. 1119-1127]. The polysaccharide component can obviously eliminate DPPH free radical [ Jianhua Xie, Mingyong Xie, shading Nie, Shen, et, al. isolation, chemical composition and antioxidant activities of a water-soluble polysaccharide from cyclic supplement (Batal.) Iljinskaja. food Chem, 2010, 119, 1626-. Cyclocarya paliurus alcohol extract can improve insulin resistance by anti-inflammation [ Cuihua Jiang, Nan Yao, Qingqing Wang, et, al. Cyclocaraya paliurus palaitus extract models adoptorienxexpression and improved insulin sensitivity by inhibition of inflammation information. journal of Ethnopharmacology, 2014, 153, 344. Anoplochia 351 ].
The corn silk [ Stigmamaydis ] is a dry style and stigma of a gramineous crop corn, and has the effects of inducing diuresis to alleviate edema, clearing heat, reducing blood pressure, calming liver and benefiting gallbladder, and the like, modern pharmacological studies show that the corn silk [ Stigmamaydis ] has the effects of reducing blood sugar, resisting gout, resisting cancer and inhibiting bacteria, and the like, flavonoid components of the corn silk can obviously reduce the ankle joint swelling of rats caused by sodium urate, the levels of inflammatory factors IL-1 β, TNF- α and MCP-1 in serum, and improve the pathological characteristics of synovial tissues of rats [ forest greeting, Dongjinxiang, and the like ], the influence of a corn silk flavone extract on gouty arthritis rats, modern food science and technology, 2015, 31 (4): 13-17], the corn silk water extract can reduce blood sugar value by increasing insulin level and repairing damaged β -cells, and the like.
Pueraria lobata (Willd) Ohwi is dried root of Pueraria lobata (Willd) Ohwi) of Leguminosae, and has effects of relieving exterior syndrome, clearing away heat, promoting fluid production, quenching thirst, invigorating yang and relieving diarrhea. Puerarin is the main drug effect component of radix Puerariae, and research shows that puerarin has effects of resisting inflammation and treating gout. In vitro experimental studies show that puerarin can inhibit the activity of xanthine oxidase, reduce the generation of uric acid, and treat gout [ prosperity, screening of traditional Chinese medicine xanthine oxidase inhibitor and inhibition kinetics research, Nanchang: university of Nanchang, 2015 ]. Puerarin can promote the expression of HK2 cells ABCG2, thereby promoting the excretion of uric acid [ zhanghong long, zhangying, laanguangfu, etc.. puerarin influences the expression of human renal proximal tubular epithelial cells ABCG 2. journal of chinese medicine in shanghai, 2016 (3): 74]. Puerarin can reduce the level of uric acid in serum of hyperuricemia patients [ Wangyong, myricetin, the influence and significance of puerarin on hyperuricemia; Nemongol traditional Chinese medicine, 2010, 29 (19): 9].
Lalang grass rhizome (Imperata cylindracea Beauv. var. major. C.E.Hubb) is dried rhizome of Cymbopogon citratus of Gramineae, has effects of cooling blood, stopping bleeding, clearing heat, and inducing diuresis, and can be used for treating hematemesis, hematuria, fever polydipsia, jaundice, edema oliguria, stranguria with heat, etc. Modern pharmacological research shows that the traditional Chinese medicine composition mainly has the effects of reducing blood sugar and blood fat, resisting oxidation and resisting inflammation. The cogongrass rhizome water decoction can relieve the mouse pinnacle swelling caused by xylene and relieve the rat hind toe swelling caused by carrageenan to exert the anti-inflammatory curative effect [ Yuxing, Houzongxian, Liu Ping, etc.. the cogongrass rhizome has the pharmacological action of anti-inflammation, Chinese clinical rehabilitation, 2006, 10 (43): 85-87]. The cogongrass rhizome polysaccharide can obviously improve the blood sugar regulation capacity of a diabetic mouse, and can obviously improve the blood lipid index [ red yu, Lichao, Yujian, and the like ] in the diabetic mouse, the cogongrass rhizome polysaccharide improves the research of the glycolipid metabolism of the mouse, the food science, 2012 and 33 (19): 302-305].
The invention selects cyclocarya paliurus, corn stigma, radix puerariae and rhizoma imperatae to carry out prescription, and utilizes the radix puerariae to reduce the generation of uric acid and promote the excretion of uric acid, thereby playing the anti-gout effect from the source; the corn stigma is utilized to realize the effect of treating gout and simultaneously generate the effect of reducing blood sugar, and simultaneously, hyperglycemia complications caused by gout are obviously improved; cyclocarya paliurus has a treatment effect on gout through antioxidant and anti-inflammatory drug effects; the cogongrass rhizome treats gout and hyperlipidemia complications caused by gout by resisting inflammation and reducing blood sugar.
The traditional Chinese medicine composition disclosed by the invention is simple in raw material components and simple and convenient in preparation process, can retain bioactive components of the components, and fully exerts the pharmacological action of the components in the composition. The traditional Chinese medicine composition can treat gout by resisting oxidation and inflammation, can reduce the generation of uric acid from the source and promote the excretion of uric acid to play the anti-gout effect, and can treat complications such as hyperglycemia, hyperlipidemia and the like caused by gout. Has the characteristics of safety and no toxic or side effect, and is suitable for long-term administration of gout patients.
Detailed Description
Example 1
A traditional Chinese medicine composition for treating gout comprises, by weight, 40 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of lalang grass rhizome.
The specific implementation steps are as follows:
a) weighing 40 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae, placing the materials in an extraction tank, and adding distilled water which is 8 times of the total mass of the raw materials into the extraction tank to enable the distilled water to fully immerse the raw material mixture.
b) Decocting at 80-100 deg.C for 3 times, each for 1-2 hr, filtering the hot filtrate, and mixing the filtrates.
c) Concentrating the combined filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the thick extract in a vacuum drying oven at 60 deg.C to obtain dry powder.
e) Packaging the dry powder.
Example 2
A traditional Chinese medicine composition for treating gout comprises, by weight, 60 parts of cyclocarya paliurus, 25 parts of corn stigma, 15 parts of radix puerariae and 15 parts of lalang grass rhizome.
The specific implementation steps are as follows:
a) weighing 60 parts of cyclocarya paliurus, 25 parts of corn stigma, 15 parts of radix puerariae and 15 parts of rhizoma imperatae, placing the materials in an extraction tank, and adding distilled water 9 times of the total mass of the raw materials into the extraction tank to enable the distilled water to fully immerse the raw material mixture.
b) Decocting at 80-100 deg.C for 3 times, each for 1-2 hr, filtering the hot filtrate, and mixing the filtrates.
c) Concentrating the combined filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the thick extract in a vacuum drying oven at 60 deg.C to obtain dry powder.
e) Packaging the dry powder.
Example 3
A traditional Chinese medicine composition for treating gout comprises, by weight, 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of lalang grass rhizome.
The specific implementation steps are as follows:
a) weighing 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae, placing the materials in an extraction tank, and adding distilled water which is 10 times of the total mass of the raw materials into the extraction tank to enable the distilled water to fully immerse the raw material mixture.
b) Decocting at 80-100 deg.C for 3 times, each for 1-2 hr, filtering the hot filtrate, and mixing the filtrates.
c) Concentrating the combined filtrate at 60 deg.C under reduced pressure to obtain soft extract with relative density of 1.20-1.30.
d) Drying the thick extract in a vacuum drying oven at 60 deg.C to obtain dry powder.
e) Packaging the dry powder.
Example 4 clinical effects of a Chinese medicinal composition for treating gout
Firstly, gout patients with clinically confirmed diagnosis are selected to eliminate gout false positive patients, so that the experimental result is more objective, real and credible.
Inclusion criteria for gout patients a screen of gout patients was performed in clinical trials with gout classification criteria determined by the American College of Rheumatology (ACR)/european antirheumatic union (EULAR) in 2015.
The gout classification diagnosis standard comprises 3 items and 8 items, the number of the items is 23, and gout can be diagnosed when the actual condition of a patient meets 8. The criteria comprehensively assessed the clinical characteristics of patients from clinical parameters (1-4 strips), laboratory parameters (5-6 strips) and imaging parameters (7-8 strips).
From 100 suspected gout patients who were clinically diagnosed, 90 patients were diagnosed as gout patients, 60 of which were the first acute gout attack patients, 16 of which were the recurrent patients of gout, and 14 of which were the chronic gout patients with complications of hyperglycemia and hyperlipidemia, using the above diagnostic criteria.
The composition extract was obtained according to the preparation recipe and process of example three. The composition is administered with 10 g/bag, and the dosage of the patient is 1 bag per time, and the composition is administered with boiled water in the morning and evening respectively for 30 days. The therapeutic effect is shown in table 1.
TABLE 1 therapeutic Effect of the compositions of the present invention
The treatment effect on gout patients is as follows:
as can be seen from table 1, the traditional Chinese medicine composition of the present invention has fast onset of therapeutic effect on patients with gout, especially patients with acute gout attack; the traditional Chinese medicine composition has the characteristic of high cure rate for various gout, particularly the cure rate of 100 percent for patients with chronic gout accompanied by hyperglycemia and hyperlipidemia complications, and no adverse reaction occurs to the patients in the treatment process. Therefore, the formula can be used for treating gout and has the characteristics of safety and no toxic or side effect.
Example 5
5.1 preparation of extract
The extract is obtained according to the formula and the process of the third embodiment, any mixture of the three traditional Chinese medicines and any mixture of the two traditional Chinese medicines in the formula are extracted according to the proportion and the process of the single traditional Chinese medicine in the third embodiment, and the extract of the single traditional Chinese medicine is extracted according to the extraction process in the third embodiment.
5.2 Experimental groups
Blank group, model group, cyclocarya paliurus group, puerariae group, imperata rhizome group, stigma Maydis group, cyclocarya paliurus group (cyclocarya paliurus + puerariae root, the same below), cyclocarya paliurus group (cyclocarya paliurus + imperata rhizome, the same below), chrysoidine group (cyclocarya paliurus + stigma Maydis, the same below), puerariae rhizome group (puerariae + rhizoma imperatae, the same below), puerariae jade group (puerariae + stigma Maydis, the same below), chrysoidine group (rhizoma imperatae + stigma Maydis, the same below), cyclocarya paliurus + puerariae + rhizoma imperatae, the same below), cyclocarya paliurus group (cyclocarya paliurus + rhizoma imperatae + stigma Maydis, the same below), cyclocarya paliurus + puerariae root + rhizoma imperatae + stigma Maydis, and four traditional Chinese medicines extracted respectively form extracts, in accordance with the example, the three-component, cyclocarya paliurus + rhizoma alismatis group (cyclocarya paliurus + rhizoma imperatae), and the four traditional Chinese medicines are extracted according to the proportion and the process of the three traditional Chinese medicines) and the positive medicine group.
5.3 prophylactic administration
SD rat, 180-220 g. Animals are bred adaptively for one week, and then preventive gavage administration is carried out (the dosage of the composition and the extract of a single traditional Chinese medicine is calculated according to the crude drug amount of 2g/kg of rats and the extraction rate of the composition and the single traditional Chinese medicine respectively, and the dosage of the positive medicine is calculated according to the clinical effective dosage of the positive medicine to guide the dosage of the rats. Blank group and model group are given with 0.5% CMC-Na blank solvent, administration group is respectively according to 500mg/kg of cyclocarya paliurus group, 700mg/kg of radix puerariae group, 420mg/kg of rhizoma imperatae group, 650mg/kg of corn stigma group, 580mg/kg of radix puerariae group, 490mg/kg of radix cyanin group, 600mg/kg of green jade group, 580mg/kg of radix puerariae group, 670mg/kg of radix puerariae group, 550mg/kg of white jade group, 660mg/kg of radix puerariae group, 640mg/kg of radix puerariae group, 535mg/kg of white jade group, 610mg/kg of radix puerariae group, 580mg/kg of white jade group, 600mg/kg of formula group, 0.3mg/kg of positive group is administered by stomach irrigation, and is continuously administered for 7 days.
5.4 sodium urate-induced acute gout model
On day 6 of dosing, rats were anesthetized after the gavage was completed. 0.2mL of 0.9% normal saline is injected into the ankle joint cavity of the blank group, and 0.2mL of sodium urate crystal with the injection concentration of 20mg/mL is injected into the ankle joint cavity of the other groups, so that an acute gout model is induced.
5.5 pharmacodynamic evaluation
After the gavage was completed on day 7 of the administration, the degree of swelling of the joints of the right hind limb of the rat 24 hours after the molding was determined, blood was taken from the orbit, and the serum was separated and the contents of IL-1 β and TNF- α in the serum were measured.
And (5) experimental results. See tables 2 and 3.
TABLE 2 degree of ankle swelling
Note: in comparison with the blank set, the results,**p is less than 0.01; in comparison to the model set,#p＜0.05，##p＜0.01
compared with the blank group, the ankle swelling of the animals in the model group is obviously increased (p is less than 0.01), which indicates that the acute gout model is successfully induced; compared with a model group, the single traditional Chinese medicine, any two-component combination of the single traditional Chinese medicine, any three-component combination of the single traditional Chinese medicine and extract combination of four traditional Chinese medicines of each formula can reduce the ankle swelling degree (p is less than 0.05) of a rat, the formula group can obviously reduce the ankle swelling degree (p is less than 0.01), the formula can relieve the ankle swelling caused by the attack of acute gout of animals, the effect of the formula is better than that of other administration groups, and the purpose of treating gout can be achieved through synergistic effect of the components of the formula; compared with a model group, the positive medicine group can show the swelling degree of the ankle joint (p is less than 0.01), and the explanatory medicine can play a good role in treating acute gout. Compared with the positive medicine group, the prescription group has no significant difference, which shows that the prescription and the positive medicine have equivalent effects on treating acute gout.
TABLE 3 rat serum IL-1 β and TNF- α levels
Note: in comparison with the blank set, the results,**p is less than 0.01; in comparison to the model set,##p＜0.01，#p＜0.05
compared with a blank group, IL-1 β and TNF- α in serum of a model group are obviously increased (p is less than 0.01), which indicates that an acute gout model induced by sodium urate is successful, compared with the model group, the contents of IL-1 β and TNF- α in animal serum of a single medicine, any two traditional Chinese medicine combination, three traditional Chinese medicine combination and four traditional Chinese medicine extract group are obviously reduced (p is less than 0.05 and p is less than 0.05), the contents of IL-1 β and TNF- α in animal serum of the formula group are obviously reduced (p is less than 0.01 and p is less than 0.01) and the contents of IL-1 β and TNF- α in animal serum of the formula are obviously reduced (p is less than 0.01 and p is less than 0.01) to indicate that the formula can fully play a synergistic effect to treat gout, compared with the model group, the contents of IL- β and TNF- α in animal serum of the positive medicine can be obviously reduced (p is less than 0.01 and p is less than 0.01) to indicate that the positive gout can be treated, and compared with the acute gout treatment group, the acute gout group and the acute gout treatment group has no obvious effect.
Claims (4)
1. A traditional Chinese medicine composition for treating gout is characterized in that: the composition comprises the following raw materials in parts by weight:
40-80 parts of cyclocarya paliurus, 10-40 parts of corn stigma, 5-30 parts of kudzu root and 5-30 parts of lalang grass rhizome.
2. The traditional Chinese medicine composition for treating gout according to claim 1, wherein: the composition comprises the following raw materials in parts by weight: 80 parts of cyclocarya paliurus, 10 parts of corn stigma, 5 parts of radix puerariae and 5 parts of rhizoma imperatae.
3. The method for preparing the traditional Chinese medicine composition for treating gout according to claim 1 or 2, which is characterized by comprising the following steps: mixing the raw materials at a certain ratio, decocting, concentrating, drying, pulverizing, sieving and packaging.
4. The preparation method of the traditional Chinese medicine composition for treating gout according to claim 3, wherein the preparation method comprises the following steps: the method comprises the following specific steps:
a) adding 8-10 times of distilled water according to the total mass of the mixed raw materials;
b) decocting the mixture at 80-100 deg.C for 1-2 hr for 2-3 times;
c) concentrating the obtained decoction under reduced pressure to obtain soft extract with relative density of 1.20-1.30;
d) drying the obtained thick extract at 60-80 deg.C to obtain dry powder;
e) packaging the dry powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810957243.2A CN110833595B (en) | 2018-08-17 | 2018-08-17 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810957243.2A CN110833595B (en) | 2018-08-17 | 2018-08-17 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110833595A true CN110833595A (en) | 2020-02-25 |
| CN110833595B CN110833595B (en) | 2021-07-20 |
Family
ID=69573950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810957243.2A Active CN110833595B (en) | 2018-08-17 | 2018-08-17 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110833595B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807390A (en) * | 2021-01-22 | 2021-05-18 | 梁俊雄 | Gout tea bag and preparation method and application thereof |
| CN114098089A (en) * | 2021-10-22 | 2022-03-01 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114246933A (en) * | 2021-12-01 | 2022-03-29 | 广州宏韵医药科技股份有限公司 | Composition and food for reducing uric acid, and preparation method and application thereof |
| CN115887587A (en) * | 2022-12-20 | 2023-04-04 | 贵州米畴亨生物科技有限公司 | Mountain grass tea capable of promoting urination and reducing uric acid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940282A (en) * | 2015-06-05 | 2015-09-30 | 百花医花集团股份有限公司 | Cyclocarya paliurus preparation and preparation method thereof |
| CN107087697A (en) * | 2017-03-29 | 2017-08-25 | 广西凌云县盘古生态产业发展有限公司 | It is a kind of can anti-trioxypurine sleeping type cyclocarya paliurus tea and preparation method thereof |
-
2018
- 2018-08-17 CN CN201810957243.2A patent/CN110833595B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940282A (en) * | 2015-06-05 | 2015-09-30 | 百花医花集团股份有限公司 | Cyclocarya paliurus preparation and preparation method thereof |
| CN107087697A (en) * | 2017-03-29 | 2017-08-25 | 广西凌云县盘古生态产业发展有限公司 | It is a kind of can anti-trioxypurine sleeping type cyclocarya paliurus tea and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 刘丽娟等: "葛根治疗痛风的临床疗效", 《吉林大学学报（医学版）》 * |
| 律广富等: "玉米须总黄酮提取物对痛风性肾病大鼠肾脏尿酸***的影响", 《中成药》 * |
| 无: "降糖降压降血脂防痛风的青钱柳", 《HTTPS://WWW.JIANKE.COM/XNXGPD/5093270.HTML》 * |
| 杨长春: "《痛风这样做 止痛降尿酸》", 31 July 2018, 江苏凤凰科学技术出版社 * |
| 林贺等: "玉米须黄酮提取物对痛风性关节炎大鼠的影响", 《现代食品科技》 * |
| 马越等: "葛根提取物抗痛风性关节炎作用及机制初探", 《中药新药与临床药理》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112807390A (en) * | 2021-01-22 | 2021-05-18 | 梁俊雄 | Gout tea bag and preparation method and application thereof |
| CN114098089A (en) * | 2021-10-22 | 2022-03-01 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114098089B (en) * | 2021-10-22 | 2023-06-23 | 朗姿赛尔生物科技（广州）有限公司 | Composite peptide composition and composite peptide seasoning tea |
| CN114246933A (en) * | 2021-12-01 | 2022-03-29 | 广州宏韵医药科技股份有限公司 | Composition and food for reducing uric acid, and preparation method and application thereof |
| CN115887587A (en) * | 2022-12-20 | 2023-04-04 | 贵州米畴亨生物科技有限公司 | Mountain grass tea capable of promoting urination and reducing uric acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110833595B (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110833595B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN1964730B (en) | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same | |
| Tao et al. | Regulation effects on abnormal glucose and lipid metabolism of TZQ-F, a new kind of Traditional Chinese Medicine | |
| CN100488552C (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN104172159A (en) | Composition with auxiliary protection effect on alcoholic liver injury and preparation method thereof | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101879297B (en) | Prostate recovery capsules of Chinese medicinal compound preparation, preparation process and application thereof | |
| CN1622819A (en) | An anti-rheumatism medicament and preparation method thereof | |
| KR100314999B1 (en) | Herbal Medicine for the Treatment of Antibacterial and Inflammatory Diseases | |
| JP4516958B2 (en) | Anti-diabetic composition | |
| Reddy | Madhuca indica: An untapped forest tree for its medicinal uses | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN106798854B (en) | Phyllanthus emblica leaf and preparation method thereof | |
| CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
| CN102688263B (en) | Geranium strictipes effective part preparation and medical use of geranium strictipes for preventing and curing colonitis | |
| CN101199652B (en) | Medicament for treating acute, subacute eczema and preparing method thereof | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| WO2013138964A1 (en) | Application of iso-daphnetin compound in preparation of anti-diabetic medicines | |
| KR100315001B1 (en) | Herbal Medicine for the Treatment of Diabetes Mellitus Containing Enteric Bellflower Extract | |
| CN102755568B (en) | Health-care product for assisting in decreasing blood sugar and preparation method thereof | |
| CN101167887A (en) | Orally-administered matrimony vine single preparation traditional Chinese medicine for treating diabetes and preparation method thereof | |
| WO2006015522A1 (en) | A capsule for regulation of blood pressure and hyperlipemia and prevention and treatment of cardiovascular and cerebrovascular diseases | |
| CN114767760B (en) | A composition with liver protecting effect | |
| CN107334988B (en) | Traditional Chinese medicine composition for treating pulmonary abscess |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |